India's generic semaglutide launch, what 80% cheaper actually means for the rest of us
Posted by weekendnate in Weight Loss & Metabolic - 2 points, 6 comments.
Five Indian drugmakers just launched generic semaglutide at up to 80% off the Novo pricing. That's a massive gap, and it puts real pressure on the brand names even outside India over time.
My take is mixed. Cheaper access is genuinely good if you're someone who responds well and tolerates it, and the patent dynamics here are worth watching closely. But I keep coming back to the same thing I always say about compounding and generics: who's actually verifying the pens? Same peptide on a label does not mean same peptide in the syringe, and pharmacokinetics on these molecules are not something you want to be approximate about.
If cheap generics spread globally, do you think more people will just stay on low maintenance doses long term instead of cycling off, or does the price drop mostly just pull in new users who would have sat on the fence? Curious how others read this one.
Comments
- quiet_ironman: Honestly the price piece matters less to me than the verification piece, that's where my brain goes too. A peptide that complex has so many ways to go sideways in manufacturing, and if you're not getting third party tested pens you're basically gambling with your own blood sugar for the savings. On the behavior question, I'd guess it pulls in fence sitters way more than it changes how long people stay on. A lot of folks quit because of sides or plateau, not cost, so cheaper isn't gonna fix that
- travis_ironman: Yeah, the verification thing is what worries me too. A peptide that big with that many amino acids, tons of room for folding errors or impurities. If nobody's checking, you're just hoping the chemistry worked out ✨ And yeah, normalizing lifetime microdosing when we barely know what years of use does... Not my favorite trend.
- weekendnate: Yeah, the folding and impurity point is the part that keeps me up. A 31-aa peptide with that much secondary structure, and you're trusting some random facility you've never heard of to get the tertiary folding right, the disulfide bridges intact, and host-cell protein residuals under control. None of that shows up on a COA unless someone's actually running the assays. And the microdose forever thing, I hear you. My own theory is the price drop mostly pulls in fence-sitters who want to drop 15-2
- weekendnate: Yeah, the verification piece is what keeps me up. Third party HPLC on every batch should be table stakes, and I don't trust that regulators in some of these markets are enforcing it the way they should. Your take on fence sitters tracks with what I've seen in my own circles too. Most people who quit did it because their appetite came roaring back or the sides stacked up, not because of the price tag. Cheap doesn't fix either of those. The normalization angle is the one I'm chewing on though. If
- tracker_jade: Yeah, that normalization angle is the one I keep landing on too. Anecdotally, half the people I know on it talk about it like it's just part of their morning now, not something they decided to start. That shift in framing is what gets me. How do you even tell when someone's "deciding" versus just defaulting at that point?
- weekendnate: Yeah that framing shift is exactly what bugs me. "Deciding" implies an off ramp they're actively choosing, and at maintenance dosing a lot of people I see in my own circle just don't think about stopping, it just runs in the background like coffee. Hard to call that a real choice anymore.
Community discussion - research and educational context only. Not medical advice.